You are here: Industry Insights > Merck

News List

Merck’s Keytruda obtains EC approval as adjuvant therapy for kidney cancer Pharmaceutical-Technology
January 28, 2022
In a Phase III trial, Keytruda lowered the disease recurrence or mortality risk by 32% versus placebo.
Merck and Ridgeback make pact with UNICEF for antiviral COVID-19 medicine supply CPhIonline
January 20, 2022
The agreement will enable millions of patients in more than 100 low- and middle-income countries to gain access to molnupiravir.
Merck, Ridgeback Ink Molnupiravir Supply Agreement with UNICEF contractpharma
January 18, 2022
Allocate 3 million courses of the oral antiviral to be provided in first half of 2022 for use in low- and middle-income countries.
Absci and Merck collaborate to develop new enzymes pharmaceutical-business-review
January 10, 2022
drug and target discovery company Absci has signed a research collaboration with Merck to produce new enzymes.
Absci Enters Research Collaboration with Merck contractpharma
January 07, 2022
Will deploy its Bionic Protein non-standard amino acid technology to produce enzymes tailored to Merck’s biomanufacturing applications.
Dr Reddy’s to launch generic COVID-19 Merck drug at about 50 cents a pill ExpressPharma
January 05, 2022
Dr Reddy’s Laboratories will launch its generic version of Merck’s antiviral COVID-19 pill, Molnupiravir, and price it at Rs 35 ($0.4693) per capsule, a company spokesperson said yesterday.
Merck and Ridgeback’s Molnupiravir Receives U.S. FDA Emergency Use Authorization for the Treatment of High-Risk Adults With Mild to Moderate COVID-19 Drugs
December 27, 2021
Merck (NYSE: MRK), known as MSD outside the United States and Canada, and Ridgeback Biotherapeutics today announced that the U.S. Food and Drug Administration (FDA) has granted Emergency Use Authorization...
Merck, Ridgeback to supply 1.75 million molnupiravir courses to UK Pharmaceutical-Business-Review
December 24, 2021
Molnupiravir is an orally administered form of a potent ribonucleoside analogue that blocks the SARS-CoV-2 replication. It is planned to be sold under the trademark Lagevrio in the UK.
UK government to purchase additional 1.75 million courses of Molnupiravir expresspharma
December 23, 2021
With this additional procurement agreement, which follows a previously announced agreement for 480,000 courses of treatment...
Merck Receives Positive EU CHMP Opinion for KEYTRUDA? as Adjuvant Therapy for Renal Cell Carcinoma AmericanPharmaceuticalReview
December 20, 2021
Merck announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending approval of KEYTRUDA...